Octapharma has published its financial breakdown for 2009, a year which saw the company post record-high profit and turnover levels.
The pharmaceutical company's gross profit for the period came to 415 million euros (373.3 million pounds), up from 367 million the previous year, while net turnover increased by 14 per cent year-on-year to just over one billion euros.
According to the fiscal report, the firm was also able to maintain its margins and operating costs at acceptable levels through improved efficiency at its production plants, as well as increased cost awareness.
Octapharma chairman Wolfgang Marguerre also praised the contribution and performance of the company's employees.
The report concluded: "The outlook for Octapharma in the year 2010 remains challenging though cost awareness and productivity should enable an outcome at an almost unchanged level."
Last month, the company commenced a phase III clinical trial of a new high-purity intravenous immunoglobulin treatment designed for sufferers of immune deficiencies.See all the latest jobs in Pharmaceutical